← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV14행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
CGTStandard DatabasestalePreclinical
Auto CAR-T (Auto CAR-T)
Hebei Senlang Biotechnology Inc., …·Plasma Cell Tumors
1 trials
Overview
Program
Auto CAR-T
Overview
Company
Hebei Senlang Biotechnology Inc., Ltd.
Overview
Modality
CGT
Overview
Target
Plasma Cell Tumors
Overview
Indication
Plasma Cell Tumors
Overview
Phase
PRECLINICAL
Overview
Status
ACTIVE
Overview
Content status
Standard Database
Overview
Data Confidence
Data Confidence · Medium
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter.. Chimeric antigen receptor (CAR) T cell therapies have shown remarkable efficacy in hematological malignancies, yet translation to solid tumors has been hindered by immunosuppressive tumor microenvironments, reduced T cell persistence and on-target/off-tumor toxicities. Constitutive CAR expression, t…
Clinical
Safety signal
Auto-inducible expression of chimeric antigen receptor T cells using the NR4A1 promoter.. Chimeric antigen receptor (CAR) T cell therapies have shown remarkable efficacy in hematological malignancies, yet translation to solid tumors has been hindered by immunosuppressive tumor microenvironments, reduced T cell persistence and on-target/off-tumor toxicities. Constitutive CAR expression, t…
Clinical
Program phase
PRECLINICAL